Startseite Kongressberichte 2021 ESMO Congress 2021 Interviews Interviews - Brustkrebs Renate Haidinger, Brustkrebs Deutschland e.V. im Interview mit Michael Untch, Berlin-Buch

DESTINY03-Studie, HER2-positiv, 2. Linie metastasiert Überlebensvorteil ? mit Trastuzumab Deruxtecan

Renate Haidinger, Brustkrebs Deutschland e.V. im Interview mitMichael Untch, Berlin-Buch:


Abstract DESTINY-Breast03


Trastuzumab Deruxtecan (T-DXd) vs Trastuzumab Emtansine (T-DM1) in Patients (Pts) With HER2+ Metastatic Breast Cancer (mBC): Results of the Randomized Phase 3 DESTINY-Breast03 Study

Cortés, et al.


T-DXd demonstrated a highly statistically significant and clinically meaningful improvement in PFS vs T-DM1 in pts previously treated with trastuzumab and taxane for HER2+ mBC. These data confirm that T-DXd is tolerable with manageable toxicity and a significant improvement in ILD profile vs studies performed in more heavily pretreated pts. This study will lead to a paradigm shift in the treatment of HER2+ mBC.